Quick Answer
MARAVAI LIFESCIENCES HOLDINGS, INC. reported Total Revenue of $185.74 million for fiscal year 2025.
MARAVAI LIFESCIENCES HOLDINGS, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $185.74M -28.3% |
$259.19M -10.3% |
$288.94M -67.3% |
$883.00M +10.5% |
$799.24M +181.3% |
$284.10M +98.5% |
| Revenue (ASC 606) | $185.74M -28.3% |
$259.19M -10.3% |
$288.94M -67.3% |
$883.00M +10.5% |
$799.24M +181.3% |
$284.10M +98.5% |
| Net Income | -$130.77M +9.7% |
-$144.85M -21.7% |
-$119.03M -154.1% |
$220.21M +21.0% |
$182.04M +104.6% |
$88.97M +2090.4% |
| Diluted EPS | -$0.90 +14.3% |
-$1.05 -16.7% |
-$0.90 -153.9% |
$1.67 +7.1% |
$1.56 -33.9% |
$2.36 +7966.7% |
| Total Assets | $770.58M -46.6% |
$1.44B -2.9% |
$1.49B -34.8% |
$2.28B +19.0% |
$1.92B +51.0% |
$1.27B |
| Cash and Equivalents | $216.89M -62.2% |
$573.17M -0.3% |
$574.96M -9.0% |
$632.14M | — | — |
| Long-Term Debt | $286.33M -44.6% |
$517.08M -0.3% |
$518.71M -0.6% |
$522.00M -0.5% |
$524.59M -0.8% |
$528.61M |
| Stockholders Equity | $212.38M -51.1% |
$434.73M +4.3% |
$416.75M -23.6% |
$545.22M +72.8% |
$315.50M +256.5% |
$88.51M -38.8% |
| R&D Expense | $17.40M -9.5% |
$19.22M +11.2% |
$17.28M -5.9% |
$18.37M +20.7% |
$15.22M +63.6% |
$9.30M +156.5% |
| Operating Income | -$215.27M +8.6% |
-$235.62M -644.5% |
-$31.65M -105.5% |
$574.22M +3.5% |
$554.64M +362.6% |
$119.90M +399.8% |
| Gross Profit | $33.99M -68.6% |
$108.31M -22.7% |
$140.20M | — | — | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $41.63M | -39.7% | -12.2% |
| Revenue (ASC 606) | September 30, 2025 | $41.63M | -39.7% | -12.2% |
| Net Income | September 30, 2025 | -$25.56M | +73.7% | +35.4% |
| Diluted EPS | September 30, 2025 | -$0.18 | +73.5% | +33.3% |
| Total Assets | September 30, 2025 | $849.19M | -33.6% | -5.3% |
| Cash and Equivalents | September 30, 2025 | $243.57M | -57.9% | -9.8% |
| Long-Term Debt | September 30, 2025 | $287.38M | -44.3% | -0.4% |
| Stockholders Equity | September 30, 2025 | $245.44M | -28.9% | -7.7% |
| R&D Expense | September 30, 2025 | $3.84M | -18.3% | -21.3% |
| Operating Income | September 30, 2025 | -$41.03M | +75.2% | +38.1% |
| Gross Profit | September 30, 2025 | $5.66M | -82.5% | -82.5% |
- MARAVAI LIFESCIENCES HOLDINGS, INC. reported Total Revenue of $185.74 million for fiscal year 2025.
- MARAVAI LIFESCIENCES HOLDINGS, INC. showed a decrease of -28.3% in Total Revenue compared to the prior fiscal year.
- MARAVAI LIFESCIENCES HOLDINGS, INC. reported Revenue (ASC 606) of $185.74 million for fiscal year 2025.
- MARAVAI LIFESCIENCES HOLDINGS, INC. showed a decrease of -28.3% in Revenue (ASC 606) compared to the prior fiscal year.
- MARAVAI LIFESCIENCES HOLDINGS, INC. reported Net Income of -$130.77 million for fiscal year 2025.
- MARAVAI LIFESCIENCES HOLDINGS, INC. showed an increase of +9.7% in Net Income compared to the prior fiscal year.
- MARAVAI LIFESCIENCES HOLDINGS, INC. reported Diluted EPS of $0.90 per share (loss) for fiscal year 2025.
- MARAVAI LIFESCIENCES HOLDINGS, INC. showed an increase of +14.3% in Diluted EPS compared to the prior fiscal year.
- MARAVAI LIFESCIENCES HOLDINGS, INC. reported Total Assets of $770.58 million for fiscal year 2025.
- MARAVAI LIFESCIENCES HOLDINGS, INC. showed a decrease of -23.6% in Total Assets compared to the prior fiscal year.
- MARAVAI LIFESCIENCES HOLDINGS, INC. reported Cash and Equivalents of $216.89 million for fiscal year 2025.
- MARAVAI LIFESCIENCES HOLDINGS, INC. showed a decrease of -32.7% in Cash and Equivalents compared to the prior fiscal year.
- MARAVAI LIFESCIENCES HOLDINGS, INC. reported Long-Term Debt of $286.33 million for fiscal year 2025.
- MARAVAI LIFESCIENCES HOLDINGS, INC. showed a decrease of -1.4% in Long-Term Debt compared to the prior fiscal year.
- MARAVAI LIFESCIENCES HOLDINGS, INC. reported Stockholders Equity of $212.38 million for fiscal year 2025.
- MARAVAI LIFESCIENCES HOLDINGS, INC. showed a decrease of -34.7% in Stockholders Equity compared to the prior fiscal year.
- MARAVAI LIFESCIENCES HOLDINGS, INC. reported R&D Expense of $17.40 million for fiscal year 2025.
- MARAVAI LIFESCIENCES HOLDINGS, INC. showed a decrease of -9.5% in R&D Expense compared to the prior fiscal year.
- MARAVAI LIFESCIENCES HOLDINGS, INC. reported Operating Income of -$215.27 million for fiscal year 2025.
- MARAVAI LIFESCIENCES HOLDINGS, INC. showed an increase of +8.6% in Operating Income compared to the prior fiscal year.
- MARAVAI LIFESCIENCES HOLDINGS, INC. reported Gross Profit of $33.99 million for fiscal year 2025.
- MARAVAI LIFESCIENCES HOLDINGS, INC. showed a decrease of -68.6% in Gross Profit compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: